Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks to Present at 37th Annual Canaccord Genuity Growth Conference

Business Wire August 4, 2017

Zymeworks Appoints Dr. Natalie Sacks to its Board of Directors

Business Wire August 3, 2017

Zymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017

Business Wire August 1, 2017

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration

Business Wire July 18, 2017

Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly

Business Wire June 12, 2017

Zymeworks Inc. Closes the Market

Canada NewsWire June 4, 2017

Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017)

Business Wire June 4, 2017

10 Biggest Mid-Day Losers For Thursday

Benzinga.com  June 1, 2017

Zymeworks Announces Closing of Partial Exercise of Over-Allotment Option for Its Initial Public Offering

Business Wire May 31, 2017

Zymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering

Business Wire May 26, 2017

Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst

Benzinga.com  May 23, 2017

Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting

Business Wire May 17, 2017

Zymeworks Reports First Quarter 2017 Financial Results

Business Wire May 15, 2017

Zymeworks to Present at UBS Global Healthcare Conference

Business Wire May 12, 2017

Zymeworks to Host First Quarter 2017 Financial Results Conference Call on May 15, 2017

Business Wire May 9, 2017

Zymeworks Thanks Resigning Directors For Their Service

Business Wire May 9, 2017

Zymeworks Announces Closing of Initial Public Offering

Business Wire May 3, 2017

IIROC Trade Resumption - Zymeworks Inc.

Newsfile April 28, 2017

IIROC Trade Halt - Zymeworks Inc.

Newsfile April 28, 2017

Zymeworks Announces Pricing of Initial Public Offering

Business Wire April 27, 2017